Novel product launches by the market players in the factor VIII deficiency treatment is expected to boost growth of the market over the forecast period. For instance, in June 2019, Novo Nordisk received marketing authorization from European commission for Esperoct in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency).
Request a sample copy of this report:- https://www.coherentmarketinsights.com/insight/request-sample/3257
Novel product launches by the market players in the factor VIII deficiency treatment is expected to boost growth of the market over the forecast period. For instance, in June 2019, Novo Nordisk received marketing authorization from European commission for Esperoct in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency). Moreover, in April 2019, Roche Products India Pvt Ltd launched hemophilia A drug emicizumab, branded as Hemlibra in India. It is indicated for prophylactic treatment for reducing frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors.
Furthermore, increasing government initiatives to promote awareness about hemophilia treatment among population is expected to propel growth of the market over the forecast period. For instance, the National Bleeding Authority (NBA) provides funding to AHCDO (Australian Hemophilia Center Directors’ Organization) for treatment and management hemophilia A. to support the effective management of hemophilia (Factor VIII Deficiency) in Australia.
The rest of the world factor VIII deficiency treatment market is expected to exhibit a CAGR of 4.7% over the forecast period (2019-2027).
Rising cases of bleeding disorders is expected to boost growth of the rest of the world factor VIII deficiency treatment market
The rest of the world factor VIII deficiency treatment market is expected to witness significant growth, owing to rising cases of hemophilia or bleeding disorders. For instance, according to the Australian Bleeding Disorders Registry 2016 statistics, in 2015 there were around 4,941 patients, who suffered from common hereditary bleeding disorders, of which 2,301 patients were diagnosed with hemophilia A, and 548 patients were diagnosed with hemophilia B in Australia. Thus, increasing prevalence of hemophilia in Australia is expected to drive demand for factor VIII deficiency treatment over the forecast period. Moreover, increasing demand for efficient therapeutics for treatment of factor VIII deficiency from emerging economies such as India is expected to drive the market growth over the forecast period. For instance, according to the World Federation of Hemophilia, 2017 statistics, in India, around 18,353 people were diagnosed with hemophilia in 2016.
Increasing healthcare expenditure and reimbursement policies in respective countries or regions are expected to drive the market growth
Latin America is expected to hold dominant position in the rest of the world factor VIII deficiency treatment market, owing to increasing per capita healthcare spending in Latin America, which is expected to drive the market growth in the region over the forecast period. For instance, according to the World Bank estimates, 2017, per capita healthcare expenditure increased significantly across Latin America during the six-year (2008-2014) interval, with an increase of 31% in Brazil, 54% in Chile, and 58% in Columbia.
Moreover, Asia Pacific is expected to be the second largest dominating region in the rest of the world factor VIII deficiency treatment market, owing to rising favorable reimbursement policies for hemophilia treatment in economies such as China, which is expected to drive the Asia Pacific market growth. For instance, according to the Chinese Ministry of Health report 2012, in China, outpatient hemophilia treatment is covered by health insurance schemes in over 80% of the cities in China, with reimbursement caps and patient co-pay requirements over 50%. Moreover, annual reimbursement is usually accounted below US$ 16,000.
Major players operating in the rest of the world factor VIII deficiency treatment market include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S.

Get the main link:- https://www.coherentmarketinsights.com/market-insight/rest-of-the-world-factor-viii-deficiency-treatment-market-3257
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: http://www.coherentchronicle.com/